1. Scrip
  2. >>R&D
  3. >>Clinical Trials

J&J Muscles Into CAR-T Field: Initiates Myeloma Studies

 
• By John Davis

An autologous CAR-T therapy in development by Janssen and Legend Biotech is expected to kick-off US clinical studies in the second half of 2018, adding to the race to apply the new technology to multiple myeloma.

SC1805_Horse Racing_ 657743737_1200.jpg
It's a race to the finish for a CAR-T multiple myeloma therapy • Source: Shutterstock

Janssen Pharmaceutical Cos. (Johnson & Johnson) has announced plans to start its Phase Ib/II clinical development program for the CAR-T therapy, JNJ-68284528, in multiple myeloma, in which it will add its expertise in treating the condition to the evolving treatment modality currently led in other disease sectors by Novartis AG's Kymriah (tisagenlecleucel) and Gilead Sciences Inc.'s Yescarta (axicabtagene ciloleucel).

Janssen's CAR-T program, which is being advanced under a collaboration with development partner Legend Biotech Corp., is set to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

More from R&D

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.